Compare Paychex, Inc. (PAYX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs ResMed Inc. — how do they compare? Paychex, Inc. trades at $104.53 (market cap $37.19B), while ResMed Inc. trades at $230.43 (market cap $31.89B). The key difference: Paychex, Inc. is the larger of the two by market cap, and Paychex, Inc. pays the higher dividend (4.56%). Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and ResMed Inc. for 51 Days on average.
| PAYX | RMD | |
|---|---|---|
Market Cap | $37.19B | $31.89B |
Volume | 3,344,316 | 618,314 |
Sector | Industrials | Health |
52-Week High | $128.59 | $277.88 |
52-Week Low | $85.57 | $182.82 |
Typical Hold Time | 56 Days | 51 Days |
Enterprise Value | $40.87B | $31.24B |
Dividend Yield | 4.56% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $104.62, up 3.02% today, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.34 beating the $1.32 estimate, and maintains robust profitability with a 27.35% net income margin. Recent news highlights a 14% stock decline despite earnings strength, raising questions about dividend sustainability amid investor focus on cash flow.
The outlook is cautiously optimistic, with a consensus price target of $111 suggesting modest upside. Key opportunities include steady revenue growth and high margins, but risks involve labor market sensitivity and elevated valuation multiples. The stock's recent volatility reflects divergent analyst views, with 67.74% holding a neutral rating.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
